Oncocyte CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Insight Molecular Diagnostics Inc. Director Lou Silverman reported a disposition of 7,700 common shares on July 1, 2026, to cover tax withholding obligations.
Andrew J. Last, a Director at Insight Molecular Diagnostics Inc., reported a transaction involving the disposition of 7,700 shares of common stock on July 1, 2026, to cover tax withholding obligations.
Director Andrew Arno reports a transaction involving the withholding of shares for tax purposes and indirect beneficial ownership of additional shares in Insight Molecular Diagnostics Inc.
Director Lou Silverman acquired 26,943 shares of Insight Molecular Diagnostics Inc. common stock via a restricted stock unit grant.
Director Andrew J. Last acquired 26,943 shares of Insight Molecular Diagnostics Inc. through a restricted stock unit grant.
Director Andrew Arno acquired 32,331 restricted stock units in Insight Molecular Diagnostics Inc. on June 11, 2026.
Broadwood Partners, L.P. reported the acquisition of 569,984 shares of Insight Molecular Diagnostics Inc. across three trading days in April 2026.
Broadwood Partners, L.P. has increased its beneficial ownership in Insight Molecular Diagnostics Inc. through a series of open market common stock purchases.
CFO Andrea S. James vested 28,302 RSUs at Insight Molecular Diagnostics, with 11,298 shares withheld for taxes, and now directly owns 206,060 shares plus 84,905 RSUs.
Insight Molecular Diagnostics’ principal accounting officer settled vested RSUs into common stock, with shares withheld to cover taxes and no open‑market sales.
Insight Molecular Diagnostics CEO Josh Riggs vested 47,170 RSUs on March 26, 2026, withheld 12,310 shares for taxes at $4.11, and now holds 38,365 common shares with 141,509 RSUs outstanding.
Broadwood Partners, a 10% owner and director, acquired 521,739 shares of Insight Molecular Diagnostics Inc. common stock in a registered direct offering.
Insight Molecular Diagnostics CFO Andrea James amended a Form 4 to clarify share dispositions related to RSU vesting and tax obligations.
Insight Molecular Diagnostics Inc.'s Chief Financial Officer, Andrea S. James, vested 50,000 shares of common stock after the company met a key public float performance condition.
Insight Molecular Diagnostics Inc. officer James Yang Liu was granted 18,000 stock options with a $3.33 exercise price.
Insight Molecular Diagnostics CFO Andrea James was granted 235,000 stock options with a $3.33 exercise price, vesting over a multi-year period.
Insight Molecular Diagnostics Inc. CEO and President Josh Riggs was granted 400,000 options to purchase common stock with an exercise price of $3.33.
Insight Molecular Diagnostics Inc. Director Lou Silverman acquired 35,000 shares of common stock through a Restricted Stock Unit grant, increasing his beneficial ownership to 36,564 shares.
Insight Molecular Diagnostics Inc. Director Andrew Arno reported the acquisition of 55,000 Restricted Stock Units, increasing his beneficial ownership in the company.
Form 4: Insight Molecular Diagnostics Director Andrew J. Last Increases Stake with Significant RSU Grant
Insight Molecular Diagnostics Inc. Director Andrew J. Last was granted 35,000 Restricted Stock Units, increasing his direct beneficial ownership to 39,509 shares.
Andrea James, CFO of Oncocyte Corp, reports the acquisition of 113,207 restricted stock units.
James Liu, VP, ACCT, Cntlr, Treasurer, and PAO of Oncocyte Corp, reports the acquisition of stock options and restricted stock units.
Oncocyte Corp CEO Josh Riggs reports the acquisition and disposal of restricted stock units.
Andrea James, CFO of Oncocyte Corp, reports purchasing 97,561 shares of common stock at $2.05 per share via a private placement, increasing her direct holdings to 151,231 shares.
Patrick W. Smith, a director of Oncocyte Corp, reports acquiring additional shares of common stock through private placements and registered direct offerings.
Broadwood Partners, L.P. acquires over 5 million shares of Oncocyte Corp common stock through a direct offering and private placement, becoming a 10% owner.
Director Patrick W. Smith, through a trust, acquired additional shares of Oncocyte Corp common stock in two transactions.
Patrick W. Smith, a director of Oncocyte Corp, has increased his beneficial ownership through purchases of common stock via an irrevocable trust.
Patrick W. Smith, a director of Oncocyte Corp, reports increased indirect ownership of common stock through the Smith Irrevocable Trust.
Patrick W. Smith, a director at Oncocyte Corp, purchased 90,219 shares of common stock at a price of $2.13 per share on December 26, 2024.